Myrobalan Therapeutics

Myrobalan Therapeutics is a biotechnology company headquartered in Medford, Massachusetts, focusing on developing oral neurorestorative therapies aimed at reversing the key pathological features of underlying brain dysfunction and central nervous system (CNS) diseases. Leveraging deep insights into neural processes such as demyelination and neuroinflammation, along with innovative drug discovery tools, Myrobalan creates highly selective and brain-penetrant therapeutic candidates uniquely positioned to address CNS disorders with significant unmet medical needs. Myrobalan’s robust pipeline of novel myelin regeneration and anti-neuroinflammatory programs is advancing with strategic support from its esteemed institutional co-founders and leading chemistry partners. Committed to transforming the future, Myrobalan aims to provide patients suffering from degenerative CNS diseases with safe and effective drugs that have restorative potential.